Tirzepatide research
What PubMed holds on Tirzepatide, sorted by study design: the papers this site relies on, every clinical-trial publication PubMed tags, and the newest additions.
- PubMed records
- 2,640
- Trial publications
- 147136 randomized
- Reviews
- 962
- Human-subject tagged
- 1438
- Animal-only
- 75
- Clinical-trial publications 147
- Reviews 962
- Animal-only studies 75
- Other (in vitro, chemistry, commentary, unindexed) 1,456
Studies this site relies on
Ordered by strength of design. Conclusions are quoted verbatim from each abstract as indexed by PubMed; read the full paper before relying on any of them.
-
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
Aronne LJ, Horn DB, le Roux CW, et al.
Among participants with obesity but without diabetes, treatment with tirzepatide was superior to treatment with semaglutide with respect to reduction in body weight and waist circumference at week 72. (Funded by Eli Lilly; SURMOUNT-5 ClinicalTrials.gov number, NCT05822830.).
-
Tirzepatide for Obesity Treatment and Diabetes Prevention
Jastreboff AM, le Roux CW, Stefanski A, et al.
Three years of treatment with tirzepatide in persons with obesity and prediabetes resulted in substantial and sustained weight reduction and a markedly lower risk of progression to type 2 diabetes than that with placebo. (Funded by Eli Lilly; SURMOUNT-1 ClinicalTrials.gov number, NCT04184622.).
-
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial
Aronne LJ, Sattar N, Horn DB, et al.
In participants with obesity or overweight, withdrawing tirzepatide led to substantial regain of lost weight, whereas continued treatment maintained and augmented initial weight reduction.
-
Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity
Malhotra A, Grunstein RR, Fietze I, et al.
Among persons with moderate-to-severe obstructive sleep apnea and obesity, tirzepatide reduced the AHI, body weight, hypoxic burden, hsCRP concentration, and systolic blood pressure and improved sleep-related patient-reported outcomes. (Funded by Eli Lilly; SURMOUNT-OSA ClinicalTrials.gov number, NCT05412004.).
-
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff AM, Aronne LJ, Ahmad NN, et al.
In this 72-week trial in participants with obesity, 5 mg, 10 mg, or 15 mg of tirzepatide once weekly provided substantial and sustained reductions in body weight. (Supported by Eli Lilly; SURMOUNT-1 ClinicalTrials.gov number, NCT04184622.).
-
Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial
Rosenstock J, Wysham C, Frías JP, et al.
Tirzepatide showed robust improvements in glycaemic control and bodyweight, without increased risk of hypoglycaemia. The safety profile was consistent with GLP-1 receptor agonists, indicating a potential monotherapy use of tirzepatide for type 2 diabetes treatment.
-
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías JP, Davies MJ, Rosenstock J, et al.
In patients with type 2 diabetes, tirzepatide was noninferior and superior to semaglutide with respect to the mean change in the glycated hemoglobin level from baseline to 40 weeks. (Funded by Eli Lilly; SURPASS-2 ClinicalTrials.gov number, NCT03987919.).
-
Gastrointestinal adverse events and weight reduction in people with type 2 diabetes treated with tirzepatide in the SURPASS clinical trials
Patel H, Khunti K, Rodbard HW, et al.
Superior weight reduction with tirzepatide versus comparators appears to be independent of reported N/V/D or GI AEs.
-
Population pharmacokinetics of the GIP/GLP receptor agonist tirzepatide
Schneck K, Urva S
The covariate analysis suggested that adjustment of the dose regimen based on demographics or subpopulations was unnecessary. The tirzepatide PK model can be used to predict tirzepatide exposure for various scenarios or populations.
Clinical-trial publications in PubMed
147 records carry PubMed’s clinical-trial publication type; the 40 most recent are listed. Tagging is done by NLM indexers and occasionally includes secondary analyses.
Newest records
The most recent PubMed additions for this query at the data-edition date, regardless of design.
- The pharmacotherapy for pediatric obesity: insights and challenges from adult weight-loss medications J Diabetes Metab Disord · 2026 · Review
- GLP-1 receptor agonists in elective spine surgery: a systematic review of fusion outcomes, perioperative safety, and procedure-specific risk N Am Spine Soc J · 2026 · Review
- Weight-Loss Outcomes After Sleeve Gastrectomy Versus Tirzepatide in a Minority Cohort With Severe Obesity: Results From a Propensity Score Matched Cohort Clin Obes · 2026 · Primary study
- Cardiovascular outcomes with tirzepatide versus semaglutide in type 2 diabetes J Diabetes Metab Disord · 2026 · Primary study
- Evaluation of clinical relevance of weight nadirs and weight regain during 3 years of treatment with tirzepatide in participants with obesity or overweight and prediabetes Obes Pillars · 2026 · Primary study
- Incretin therapy prescription in a high cardiovascular risk population: Insights from a cardiology-based cardiometabolic program Am J Prev Cardiol · 2026 · Primary study
- Incretin-based injectable strategies versus intensified insulin for treatment intensification and simplification in type 2 diabetes: a systematic review and meta-analysis J Diabetes Metab Disord · 2026 · Primary study
- Association of tirzepatide with reverse cardiac remodeling and improved diastolic function in obesity-related HFpEF: A prospective real-world cohort study Int J Cardiol · 2026 · Primary study
- Clinical practice patterns and unmet needs in the use of GLP-1 receptor agonists in sleep medicine: A pan-European survey performed in the European sleep apnoea database network Pulmonology · 2026 · Primary study
- One receptor, two opposite approaches: efficacy and tolerability of GIPR agonism and antagonism in obesity pharmacotherapy Appetite · 2026 · Review